His way: Greg Verdine is building a new kind of drug, with backing from a different kind of investor
After helping spearhead the launch of a long string of biotechs over the years from his prestigious perch at Harvard, Greg Verdine is now devoting the bulk of his time to leading the effort on growing two biotechs from scratch. And he’s just chalked up a $66 million round to move one of them — FogPharma — into the clinic next year with a new technology he’s convinced can break its way into therapeutic territories that have remained off limits to developers up to now.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
